MARISSA BOTTOS: Open Payments
NPI 1639720972 · LA PORTE, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,297 in 96 payments from 17 companies in 2025. Trend: 2023 $3,020 · 2024 $1,511 · 2025 $2,297
Food & beverage: $2,288Education: $9
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 32 | $610 |
| Janssen Biotech, Inc. | 10 | $527 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $303 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 16 | $220 |
| Madrigal Pharmaceuticals | 4 | $207 |
| VIVUS LLC | 4 | $80 |
| Ardelyx, Inc. | 3 | $79 |
| Celltrion USA Inc. | 2 | $44 |
| Aimmune Therapeutics, Inc. | 2 | $43 |
| Regeneron Healthcare Solutions, Inc. | 1 | $37 |
Products named: TREMFYA, RINVOQ, ENTYVIO, REZDIFFRA, XIFAXAN, SKYRIZI, EOHILIA, PANCREAZE.
Industry payments across IN — which companies pay providers there.
